Skip to main content

MGNX

Stock

MGNX

Stock
Health Care
Biotechnology

Performance overview

MGNX Price
Price Chart

Forward-looking statistics

Beta
2.06
Risk
87.60%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

Company info

SectorHealth Care
IndustryBiotechnology
Employees377
Market cap$283.7M

Fundamentals

Enterprise value-$40.3M
Revenue$154.1M
Revenue per employee
Profit margin-36.23%
Debt to equity47.35

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.88
Dividend per share
Revenue per share$2.45
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$3M
Put-call ratio

Macro factor sensitivity

Growth-4.6
Credit-24.8
Liquidity+13.9
Inflation-4.3
Commodities-2.4
Interest Rates-4.2

Valuation

Dividend yield0.00%
PEG Ratio-0.61
Price to sales0.60
P/E Ratio-0.61
Enterprise Value to Revenue-0.26
Price to book1.16

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

4 Medical Product Stocks to Watch From a Challenging Industry

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

Zacks Investment Research (May 21, 2025)
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial

MacroGenics Inc. MGNX announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).

Benzinga (July 31, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free